Polo-like kinases inhibitors are novel drug targets of cancer therapeutics
(Note: all the sources listed in the “Balanced” section)
We will lose an estimated 9.6 million people due to cancer this year according to the World Health Organization. The report, published in September, also says that cancer is now the second leading cause of death across the globe.
Doctors today are turning to Polo-like kinases in order to develop anti-cancer drugs.
According to an article in the health journal Molecular Cell , “about 150 kinase-targeted drugs are currently being tested in clinical trials, followed by many kinase-specific inhibitors advancing in preclinical stage of drug development.”